Antidiabetic Drug-loaded Solid Lipid Nanoparticle and Its Importance in Drug Delivery

Antidiabetic Drug-loaded Solid Lipid Nanoparticle and Its Importance in Drug Delivery Vijayakumar P Balaji P

The global health challenge of diabetes mellitus continues to escalate, affecting millions of people worldwide. Managing this chronic condition necessitates lifelong treatment to control hyperglycemia and prevent complications. The delivery of antidiabetic medications can be improved by solid lipid nanoparticles (SLNs). This review provides an overview of current research on antidiabetic-loaded SLNs, summarizing their efficacy, safety, and challenges. Various antidiabetic agents, including insulin, metformin, sulfonylureas, and GLP-1 agonists, have been successfully encapsulated into SLNs, offering improved pharmacokinetic profiles and therapeutic outcomes. Despite their potential, optimization of SLN formulations, scale-up challenges, and translation to clinical practice remain areas requiring further investigation. With ongoing advancements in nanotechnology and drug delivery, antidiabetic-loaded SLNs hold promise for revolutionizing diabetes therapy and improving patient care
03 25 2024 531 536 http://creativecommons.org/licenses/by-nc-nd/4.0 10.25258/ijddt.14.1.73 https://impactfactor.org/PDF/IJDDT/14/IJDDT,Vol14,Issue1,Article73.pdf